Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.

McAuliffe ME, Lanes S, Leach T, Parikh A, Faich G, Porter J, Holick C, Esposito D, Zhao Y, Fox I.

Curr Med Res Opin. 2015;31(9):1655-64. doi: 10.1185/03007995.2015.1065242. Epub 2015 Aug 20.

PMID:
26135040
2.

Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia.

Kolitsopoulos FM, Strom BL, Faich G, Eng SM, Kane JM, Reynolds RF.

Contemp Clin Trials. 2013 Mar;34(2):239-47. doi: 10.1016/j.cct.2012.12.001. Epub 2012 Dec 12.

PMID:
23246610
3.

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM.

Am J Psychiatry. 2011 Feb;168(2):193-201. doi: 10.1176/appi.ajp.2010.08040484. Epub 2010 Nov 1.

PMID:
21041245
4.

Cardiac safety of diabetes therapies and postmarketing requirements.

Faich GA, Stemhagen A.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):787-9. doi: 10.1002/pds.1622. No abstract available.

PMID:
18655015
5.

The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics.

Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, Kane JM.

J Clin Psychiatry. 2008 Jan;69(1):114-21.

PMID:
18312045
6.

Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation.

Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G.

Drug Saf. 2007;30(8):705-13.

PMID:
17696583
7.

Points to consider: the roles of surveillance and epidemiology in advancing drug safety.

Edwards R, Faich G, Tilson H; International Society of Pharmacovigilance.

Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):665-7. No abstract available.

PMID:
15719353
8.

Administration of parenteral iron and mortality among hemodialysis patients.

Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G.

J Am Soc Nephrol. 2004 Jun;15(6):1623-32.

9.

Clinical experience with moxifloxacin in patients with respiratory tract infections.

Faich GA, Morganroth J, Whitehouse AB, Brar JS, Arcuri P, Kowalsky SF, Haverstock DC, Celesk RA, Church DA.

Ann Pharmacother. 2004 May;38(5):749-54. Epub 2004 Mar 16.

PMID:
15026565
10.

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.

PMID:
12914871
11.

Iron administration and clinical outcomes in hemodialysis patients.

Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G.

J Am Soc Nephrol. 2002 Mar;13(3):734-44.

12.

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB.

Am J Cardiol. 2002 Feb 15;89(4):425-30.

PMID:
11835924
13.

Troglitazone (Rezulin) and hepatic injury.

Faich GA, Moseley RH.

Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):537-47.

PMID:
11828837
14.

Blood-pressure-lowering treatment.

Faich GA, Makuch R.

Lancet. 2001 Mar 3;357(9257):718. No abstract available.

PMID:
11247581
15.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
16.

Black box warnings in prescription drug labeling: results of a survey of 206 drugs.

Beach JE, Faich GA, Bormel FG, Sasinowski FJ.

Food Drug Law J. 1998;53(3):403-11. No abstract available.

PMID:
10346718
17.

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.

Faich G, Strobos J.

Am J Kidney Dis. 1999 Mar;33(3):464-70. Review.

PMID:
10070910
18.

Verapamil use in patients with cardiovascular disease: an overview of randomized trials.

Pepine CJ, Faich G, Makuch R.

Clin Cardiol. 1998 Sep;21(9):633-41.

19.

Effect of onychomycosis on quality of life.

Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ.

J Am Acad Dermatol. 1998 May;38(5 Pt 1):702-4.

PMID:
9591814
20.

Drug to treat obesity: editorial writer responds.

Faich GA.

CMAJ. 1997 Apr 1;156(7):978. No abstract available.

21.

US adverse drug reaction surveillance 1989-1994.

Faich GA.

Pharmacoepidemiol Drug Saf. 1996 Nov;5(6):393-8.

PMID:
15073810
22.

Conflicts of interest--editorialists respond.

Manson JE, Faich GA.

N Engl J Med. 1996 Oct 3;335(14):1064-5. No abstract available.

23.

Pharmacotherapy for obesity -- do the benefits outweigh the risks?

Manson JE, Faich GA.

N Engl J Med. 1996 Aug 29;335(9):659-60. No abstract available.

PMID:
8687523
24.

FDA and drug approval.

Faich GA.

J Vasc Interv Radiol. 1995 Nov-Dec;6(6 Pt 2 Suppl):24S. No abstract available.

PMID:
8770838
25.

Kidney failure and analgesic drugs.

Faich G.

N Engl J Med. 1995 Jun 1;332(22):1514; author reply 1515-6. No abstract available.

PMID:
7739693
27.

Postmarketing surveillance: beyond MEDWatch.

Faich GA.

JAMA. 1993 Nov 10;270(18):2180. No abstract available.

PMID:
8411596
28.

Effects of exposure to benzodiazepine during fetal life.

Bergman U, Rosa FW, Baum C, Wiholm BE, Faich GA.

Lancet. 1992 Sep 19;340(8821):694-6.

PMID:
1355799
29.

Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine.

Jolson HM, Bosco L, Bufton MG, Gerstman BB, Rinsler SS, Williams E, Flynn B, Simmons WD, Stadel BV, Faich GA, et al.

J Natl Cancer Inst. 1992 Apr 1;84(7):500-5.

PMID:
1545440
30.

National adverse drug reaction reporting. 1984-1989.

Faich GA.

Arch Intern Med. 1991 Aug;151(8):1645-7.

PMID:
1872669
31.

Postmarketing drug surveillance studies.

Faich GA.

Clin Pharmacol Ther. 1991 May;49(5):597. No abstract available.

PMID:
2029834
32.

Diarrhea after misoprostol in Crohn disease.

Faich GA, Frick MF, Koffer H.

Ann Intern Med. 1991 Feb 15;114(4):342. No abstract available.

PMID:
1899013
33.

Pharmacoepidemiology and clinical research.

Faich GA.

J Clin Epidemiol. 1991;44(8):821-2. No abstract available.

PMID:
1941034
34.

Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project.

Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ Jr, Green M, Andrews LG, Faich GA.

JAMA. 1990 Apr 4;263(13):1785-8.

PMID:
2313850
35.

International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.

Faich GA, Castle W, Bankowski Z.

Int J Clin Pharmacol Ther Toxicol. 1990 Apr;28(4):133-8.

PMID:
2338366
36.

A method of pharmacoepidemiologic analysis that uses computerized Medicaid.

Gerstman BB, Lundin FE, Stadel BV, Faich GA.

J Clin Epidemiol. 1990;43(12):1387-93.

PMID:
2254776
37.

Drug banning and the regulatory process.

Faich GA.

J Clin Epidemiol. 1990;43(9):1014-6. No abstract available.

PMID:
2213071
38.

Record linkage for postmarketing surveillance.

Faich GA.

Clin Pharmacol Ther. 1989 Oct;46(4):479-80. No abstract available.

PMID:
2791451
39.

The future of automated record linkage for postmarketing surveillance: a response to Shapiro.

Faich GA, Stadel BV.

Clin Pharmacol Ther. 1989 Oct;46(4):387-9. No abstract available.

PMID:
2791441
40.

Morbidity and mortality among low birth weight infants exposed to an intravenous vitamin E product, E-Ferol.

Arrowsmith JB, Faich GA, Tomita DK, Kuritsky JN, Rosa FW.

Pediatrics. 1989 Feb;83(2):244-9.

PMID:
2492378
41.

Physician knowledge, attitudes, and behavior related to reporting adverse drug events.

Rogers AS, Israel E, Smith CR, Levine D, McBean AM, Valente C, Faich G.

Arch Intern Med. 1988 Jul;148(7):1596-600.

PMID:
3382304
42.

National adverse drug reaction surveillance. 1986.

Faich GA, Dreis M, Tomita D.

Arch Intern Med. 1988 Apr;148(4):785-7.

PMID:
3355297
43.

The importance of adverse reaction reporting by physicians. Suprofen and the flank pain syndrome.

Rossi AC, Bosco L, Faich GA, Tanner A, Temple R.

JAMA. 1988 Feb 26;259(8):1203-4.

PMID:
3276945
44.

Prescription drug use in 1984 and changes over time.

Baum C, Kennedy DL, Knapp DE, Juergens JP, Faich GA.

Med Care. 1988 Feb;26(2):105-14.

PMID:
3339912
45.

Rhode Island physicians' recognition and reporting of adverse drug reactions.

Scott HD, Rosenbaum SE, Waters WJ, Colt AM, Andrews LG, Juergens JP, Faich GA.

R I Med J. 1987 Jul;70(7):311-6. No abstract available.

PMID:
3476980
46.

Reassurance about generic drugs.

Faich GA, Morrison J, Dutra EV Jr, Hare DB, Rheinstein PH.

N Engl J Med. 1987 Jun 4;316(23):1473-5. No abstract available.

PMID:
3574426
47.

National patterns of aspirin use and Reye syndrome reporting, United States, 1980 to 1985.

Arrowsmith JB, Kennedy DL, Kuritsky JN, Faich GA.

Pediatrics. 1987 Jun;79(6):858-63.

PMID:
3588140
48.

National adverse drug reaction surveillance: 1985.

Faich GA, Knapp D, Dreis M, Turner W.

JAMA. 1987 Apr 17;257(15):2068-70.

PMID:
3560382
49.

Ulcerogenicity of piroxicam: an analysis of spontaneously reported data.

Rossi AC, Hsu JP, Faich GA.

Br Med J (Clin Res Ed). 1987 Jan 17;294(6565):147-50.

50.

Risks and indications of phenylbutazone: another look.

Faich GA.

Pharmacotherapy. 1987 Jan-Feb;7(1):25-7.

PMID:
3575138

Supplemental Content

Support Center